$NMTC
___________________________
CATALYSTS:
1. Disruptive next-generation diagnostic electrodes advancing a new era in neuroscience; foundational technology initially developed in collaboration with Mayo Clinic, a shareholder of the Company.
2. Strategic partnership with Zimmer Biomet (NYSE:ZBH, ~$27B mkt cap) to exclusively commercialize and distribute EVO® diagnostic electrodes; accelerated payment of $3.5 million received in August 2022.
3. Potential to penetrate large disease populations including epilepsy, Parkinson’s disease, and spinal cord stimulation, with total addressable markets of $1+ billion, $5+ billion, and $10+ billion, respectively.
4. Multi-billion market opportunity for combination devices; potential for technology adaptation and entry into AI and machine learning markets.
5. Platform technology with licensing potential for applications in urinary incontinence, pain management, hypertension, depression, and other related neurological disorders.
6. Ample capital resources to support upcoming commercial and development catalysts including the commercial launch of the Evo sEEG diagnostic line, and further development of OneRF and a thin-film-based SCS electrode system.
Leadership with deep expertise in medical device technology, marketing, and business development; world-class board of directors; esteemed scientific and physician advisory boards.
_______________________________________________________________________________
$NMTC *** $NMTC *** $NMTC *** NMTC *** $NMTC *** $NMTC
Recent NMTC News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2025 12:15:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2025 12:01:14 PM
- NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6% • GlobeNewswire Inc. • 05/13/2025 11:30:00 AM
- NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor • GlobeNewswire Inc. • 05/12/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2025 08:30:09 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/09/2025 07:47:21 PM
- NeuroOne® to Report Second Quarter Fiscal Year 2025 Financial Results on Tuesday, May 13 at 8:30 a.m. Eastern Time • GlobeNewswire Inc. • 05/01/2025 01:55:00 PM
- NeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain • GlobeNewswire Inc. • 04/23/2025 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2025 09:11:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2025 08:44:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2025 08:34:52 PM
- NeuroOne® Issues Letter to Shareholders • GlobeNewswire Inc. • 04/16/2025 01:00:00 PM
- NeuroOne® OneRF® Technology Success Story Featured on Fox News • GlobeNewswire Inc. • 04/14/2025 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2025 08:47:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2025 08:38:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2025 08:30:58 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/04/2025 08:05:27 PM
- NeuroOne Medical Technologies Corporation Announces Pricing of $8.0 Million Public Offering of Common Stock • GlobeNewswire Inc. • 04/04/2025 12:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/03/2025 08:08:56 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/03/2025 08:06:01 PM
- NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 04/03/2025 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2025 08:11:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2025 07:56:00 PM
- NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today’s Marketplace - Update • GlobeNewswire Inc. • 03/18/2025 05:12:00 PM
- NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today’s Marketplace • GlobeNewswire Inc. • 03/18/2025 01:00:00 PM
Lingerie Fighting Championships Coming to the UK for July 4 & 6 Events • BOTY • May 19, 2025 10:00 AM
VAYK Projects to Report Over $400K Q1 Revenue • VAYK • May 15, 2025 9:00 AM
Veri Medtech (VRHI) Reaches $100 Million Revenue Milestone • VRHI • May 15, 2025 8:00 AM
Cannabix Enters Sales Distribution Agreement with Australian Distributor for BreathLogix Autonomous Alcohol Breathalyzer • BLO • May 14, 2025 8:51 AM
North Bay Resources Announces Resource Estimate of 474,000 ounces at Fran Gold Project, British Columbia • NBRI • May 13, 2025 9:58 AM
UC Asset Filed for Public Offering of 8% Dividend Preferred Units • UCASU • May 12, 2025 9:55 AM